Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$27.21 - $39.48 $1.82 Million - $2.63 Million
-66,720 Reduced 78.25%
18,542 $530,000
Q4 2023

Feb 08, 2024

SELL
$21.2 - $31.03 $2.58 Million - $3.78 Million
-121,831 Reduced 58.83%
85,262 $2.61 Million
Q3 2023

Oct 31, 2023

SELL
$26.2 - $36.08 $1.22 Million - $1.68 Million
-46,529 Reduced 18.35%
207,093 $5.56 Million
Q2 2023

Aug 11, 2023

BUY
$25.16 - $41.38 $76,511 - $125,836
3,041 Added 1.21%
253,622 $9.04 Million
Q1 2023

May 11, 2023

BUY
$23.68 - $38.51 $108,454 - $176,375
4,580 Added 1.86%
250,581 $6.36 Million
Q4 2022

Feb 13, 2023

BUY
$28.0 - $40.56 $739,564 - $1.07 Million
26,413 Added 12.03%
246,001 $9.98 Million
Q3 2022

Nov 14, 2022

BUY
$29.63 - $48.31 $6.03 Million - $9.84 Million
203,593 Added 1272.85%
219,588 $7.26 Million
Q3 2021

Nov 10, 2021

SELL
$58.38 - $84.96 $105,784 - $153,947
-1,812 Reduced 10.18%
15,995 $999,000
Q2 2021

Aug 11, 2021

SELL
$62.15 - $90.32 $244,249 - $354,957
-3,930 Reduced 18.08%
17,807 $1.48 Million
Q3 2020

Nov 13, 2020

SELL
$33.21 - $51.27 $2.13 Million - $3.3 Million
-64,280 Reduced 74.73%
21,737 $936,000
Q2 2020

Aug 12, 2020

SELL
$26.12 - $43.27 $2.83 Million - $4.69 Million
-108,433 Reduced 55.76%
86,017 $3.72 Million
Q1 2020

May 14, 2020

SELL
$20.56 - $63.12 $1.74 Million - $5.34 Million
-84,640 Reduced 30.33%
194,450 $5.59 Million
Q4 2019

Feb 12, 2020

BUY
$28.14 - $73.01 $1.04 Million - $2.7 Million
36,915 Added 15.24%
279,090 $17.7 Million
Q3 2019

Nov 12, 2019

BUY
$26.26 - $34.86 $1.93 Million - $2.56 Million
73,345 Added 43.44%
242,175 $6.82 Million
Q2 2019

Aug 09, 2019

BUY
$17.43 - $28.82 $2.94 Million - $4.87 Million
168,830 New
168,830 $4.47 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $1.96B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Panagora Asset Management Inc Portfolio

Follow Panagora Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Panagora Asset Management Inc with notifications on news.